Semaglutide, liraglutide, exenatide, or dulaglutide, which belong to the GLP-1 receptor agonists, are broadly used in type II diabetes mellitus and obesity treatment. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.